Education
About Us
Working with TipRanks
Follow Us
Lipigon Pharmaceuticals AB (SE:LPGO)
:LPGO
LPGO Stock Chart & Stats
kr0.01
>-kr0.01(-5.84%)
At close: 4:00 PM EST
kr0.01
>-kr0.01(-5.84%)
Day’s Range― - ―
52-Week Range<kr0.01 - kr0.28
Previous CloseN/A
Volume77.02K
Average Volume (3M)2.79M
Market Cap
kr6.67M
Enterprise Value-kr9.93M
Total Cash (Recent Filing)kr16.60M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Feb 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding605,933,700
10 Day Avg. Volume2,063,232
30 Day Avg. Volume2,789,495
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)2.06
Price to Sales (P/S)1.55
P/FCF Ratio-0.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free capital structure reduces refinancing and interest-rate risk and preserves strategic optionality. For a clinical-stage biotech this durable flexibility supports sustained R&D spending or partnering negotiations without near-term fixed obligations that would constrain development choices.
Focused RNA Cardiometabolic PipelineConcentrating on RNA therapies for lipid disorders targets a large, chronic market with clear unmet needs. RNA modalities benefit from structural R&D momentum and partner interest, improving long-term commercialization odds and licensing attractiveness versus unfocused pipelines.
Clear Partnering/licensing Monetization PathA business model oriented to upfronts, milestones and royalties is durable for small biotechs: it enables de-risking via partners, limits the need for near-term commercial infrastructure, and provides established exit/value-capture routes if clinical data validate candidates.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow at this magnitude materially raises funding risk. Over the next 2-6 months the company will likely need new capital or partner funding to maintain programs, creating dilution risk and potential delays in R&D timetables.
Very Low And Declining RevenueMinimal and falling revenue, combined with persistent losses, indicate no commercial engine to fund operations. This structural absence of recurring cash inflows forces dependence on external capital or deals, limiting runway and bargaining power with potential partners.
Material Equity Swings Indicate Funding RelianceLarge fluctuations in equity levels point to periodic capital raises or accounting swings to fund operations. This reliance on external funding is a durable vulnerability: it risks dilution, can constrain strategic choices, and ties program continuity to volatile financing conditions.
LPGO FAQ
What was Lipigon Pharmaceuticals AB’s price range in the past 12 months?
Lipigon Pharmaceuticals AB lowest stock price was <kr0.01 and its highest was kr0.28 in the past 12 months.
What is Lipigon Pharmaceuticals AB’s market cap?
Lipigon Pharmaceuticals AB’s market cap is kr6.67M.
When is Lipigon Pharmaceuticals AB’s upcoming earnings report date?
Lipigon Pharmaceuticals AB’s upcoming earnings report date is Feb 26, 2026 which is in 10 days.
How were Lipigon Pharmaceuticals AB’s earnings last quarter?
Lipigon Pharmaceuticals AB released its earnings results on Nov 20, 2025. The company reported -kr0.012 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.012.
Is Lipigon Pharmaceuticals AB overvalued?
According to Wall Street analysts Lipigon Pharmaceuticals AB’s price is currently Overvalued.
Does Lipigon Pharmaceuticals AB pay dividends?
Lipigon Pharmaceuticals AB does not currently pay dividends.
What is Lipigon Pharmaceuticals AB’s EPS estimate?
Lipigon Pharmaceuticals AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lipigon Pharmaceuticals AB have?
Lipigon Pharmaceuticals AB has 605,933,700 shares outstanding.
What happened to Lipigon Pharmaceuticals AB’s price movement after its last earnings report?
Lipigon Pharmaceuticals AB reported an EPS of -kr0.012 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.158%.
Which hedge fund is a major shareholder of Lipigon Pharmaceuticals AB?
Currently, no hedge funds are holding shares in SE:LPGO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lipigon Pharmaceuticals AB
Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease and familial chylomicronemia syndrome; a gene therapy project for the lipodystrophy, a rare disease of altered fat distribution in the body; therapeutics for dyslipidemia, a general lipid disorder; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia, cardiovascular disease, and other metabolic diseases. The company was founded in 2010 and is based in Umeå, Sweden.